Newsletter

Pipeline, markets, policy, and science. Once a week.

You’re in. Check your inbox to confirm.

Close-up of an unlabeled amber plasma vial on a dark laboratory bench

Why Lowering Lp(a) Did Not Cut Events in 8,323 Patients

Novartis said pelacarsen lowered Lp(a) in patients already on guideline-directed care, but Lp(a)HORIZON missed its cardiovascular composite versus placebo. The first large outcomes test of the inherited risk factor now hangs over later trials from Amgen and Lilly.

Empty infusion chair and IV line in a sunlit hospital suite, suggesting outpatient myeloma care without people or text.

Can Monthly Dosing Move BCMA Bispecifics Out of the Myeloma Center?

AbbVie's etentamig beat older salvage on response and progression-free survival in Phase 3 CERVINO. The harder question is whether a single step-up and monthly intravenous schedule can loosen the REMS-and-hospitalization architecture that still gates approved BCMA T-cell engagers.

Pipeline

See all

Markets

See all

Policy

See all

Science

See all